On March 4, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported its participation in Oppenheimer’s 29th Annual Healthcare Conference (Press release, Immutep, MAR 4, 2019, View Source [SID1234534116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Conference: Oppenheimer’s 29th Annual Healthcare Conference
Dates: 19 March 2019, from 9:10 AM to 9:40 AM Eastern Standard Time
Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, USA
Presenter: Marc Voigt, CEO of Immutep
The presentation is expected to be live webcasted. A link to the webcast will be made available on the Company’s website.